High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Kim, Seokhwi ^a   Lee, Jeeyun ^b   Hong, Min Eui ^a,b   Do, In Gu ^a,b   Kang, So Young ^a   Ha, Sang Yun ^a   Kim, Seung Tae ^b   Park, Se Hoon ^b   Kang, Won Ki ^b   Choi, Min Gew ^a   Lee, Jun Ho ^a   Sohn, Tae Sung ^a   Bae, Jae Moon ^a   Kim, Sung ^a   Kim, Duk Hwan ^a   Kim, Kyoung Mee ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANALYTIC METHOD; APC GENE; ARTICLE; CANCER TISSUE; CCNE1 GENE; CDKN2A GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; GENE AMPLIFICATION; HER2 GENE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE K RAS; ONCOGENE MYC; PIK3CA GENE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SMAD4 GENE; SMO GENE; SOMATIC MUTATION; STK11 GENE; STOMACH CANCER; TP53 GENE; TUMOR GENE; AGED; ALLELE; AMINO ACID SUBSTITUTION; CANCER STAGING; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MUTATION RATE; PATHOLOGY; REPRODUCIBILITY; STOMACH TUMOR;

ADULT; AGED; ALLELES; AMINO ACID SUBSTITUTION; DNA COPY NUMBER VARIATIONS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION RATE; NEOPLASM METASTASIS; NEOPLASM STAGING; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS;

EID: 84910630641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111693     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Shin A, Kim J, Park S (2011) Gastric cancer epidemiology in Korea. J Gastric Cancer 11: 135-140.
3. Smyth EC, Cunningham D (2012) Targeted therapy for gastric cancer. Curr Treat Options Oncol 13: 377-389.
4. Wong H, Yau T (2013) Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol 6: 15-31.
5. Nadauld LD, Ford JM (2013) Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol 31: 838-839.
6. Metzker ML (2010) Sequencing technologies - the next generation. Nat Rev Genet 11: 31-46.
7. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, et al. (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4: e7887.
8. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, et al. (2011) An integrated semiconductor device enabling non-optical genome sequencing. Nature 475: 348-352.
9. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, et al. (2013) Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15: 607-622.
10. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, et al. (2013) Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 15: 171-176.
11. Simon R, Roychowdhury S (2013) Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12: 358-369.
12. Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, et al. (2003) A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 12: 791-801.
13. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, et al. (2013) Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 62: 1100-1111.
14. Deng N, Goh LK, Wang H, Das K, Tao J, et al. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684.
15. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26: 317-325.
16. Austin Tanney RDK (2010) Developing mRNA-based biomarkers from formalin-fixed paraffin-embedded tissue. Future Medicine 7: 205-211.
17. Kang G, Hwang WC, Do IG, Wang K, Kang SY, et al. (2013) Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One 8: e82770.
18. Cho EY, Park K, Do I, Cho J, Kim J, et al. (2013) Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol 26: 677-684.
19. Cho EY, Srivastava A, Park K, Kim J, Lee MH, et al. (2012) Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 44: 216-220.
20. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, et al. (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650.
21. Ha SY, Lee J, Kang SY, Do IG, Ahn S, et al. (2013) MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 26: 1632-1641.
22. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, et al. (2011) Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer. J Clin Oncol.
23. Lee SE, Kang SY, Cho J, Lee B, Chang DK, et al. (2014) Pyloric gland adenoma in Lynch syndrome. Am J Surg Pathol 38: 784-792.
24. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43: 1219-1223.
25. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44: 570-574.
26. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, et al. (2012) High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 7: e38892.
27. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, et al. (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3: 224-237.
28. Ma PC (2012) Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 79 Electronic Suppl 1: eS56-60.
29. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
30. Zhang L, Yang J, Cai J, Song X, Deng J, et al. (2013) A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep 3: 2992.
31. Network TCGAR (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature doi: 10.1038/nature13480.
32. Duan J, Zhang JG, Deng HW, Wang YP (2013) Comparative studies of copy number variation detection methods for next-generation sequencing technologies. PLoS One 8: e59128.